Trial intelligence / Profile preview

Sequential and personalized busulfan administration by pharmacokinetics in allogeneic graft conditioning

2020-003392-17Phase 2Terminated

Sponsor: Institut Paoli-Calmettes
Start: Dec 2020
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of busulfan in Acute Leukaemia and hematopoietic malignancies, sponsored by Institut Paoli-Calmettes. Primary endpoint: Non-relapse mortality at 100 days post graft. Started Dec 2020; status: terminated.

Drugs

busulfan

Conditions

Acute Leukaemiahematopoietic malignancies

Beyond the preview

Go deeper on 2020-003392-17.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-003392-17.